Haro Hartounian, PhD, Director
Dr. Haro Hartounian is a Biotechnology & Pharmaceutical executive with a record of achieving aggressive goals by positioning capital, people, intellectual property, systems, and internal disciplines for successful long-term growth.
Prior to cofounding Protagenic Therapeutics,, Dr. Hartounian was President and COO of Microislet, Inc.; a position he held from 2001 to 2006. Dr. Hartounian led the company from start-up to a successful public company, and established Microislet as a major player in the field of cell therapy for treatment of Type 1 diabetes. He took the company public and delivered an increase of $80 million in the company’s market cap within only 2 years.
Between 1998 and 2001, he served as Director, Process Development for Monsanto where he steered process R&D, formulation development, analytical method development and cGMP sourcing for a multi-functional nutritional project.
Previously, he led process development and engineering teams for Depotech Corporation where he managed process design, automation, scale-up and manufacture of aseptically filled IND and NDA sustained release products. In this role, Dr. Hartounian led the smooth transfer of technology from bench to manufacturing scale for 3 new products and received FDA approval for two products which are now on the market.
Dr. Hartounian is a member of an investment organization called the Tech Coast Angels in San Diego. He is an Entrepreneur-in-Residence with the CONNECT Springboard program assisting early-stage life science entrepreneurs in the development of their business plans and corporate strategies and is also active in numerous regional and national organizations. Dr. Hartounian was a lecturer at the Department of Bioengineering at the University of California, San Diego and Adjunct Assistant Professor at Drexel University.
Dr. Hartounian holds a Ph. D. in Chemical Engineering from the University of Delaware, and an MS in Chemical Engineering from UCLA.